7CMK image
Deposition Date 2020-07-27
Release Date 2020-08-12
Last Version Date 2024-11-06
Entry Detail
PDB ID:
7CMK
Keywords:
Title:
E30 E-particle in complex with 6C5
Biological Source:
Source Organism:
Echovirus E30 (Taxon ID: 41846)
Mus musculus (Taxon ID: 10090)
Method Details:
Experimental Method:
Resolution:
3.40 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:VP1
Chain IDs:A
Chain Length:292
Number of Molecules:1
Biological Source:Echovirus E30
Polymer Type:polypeptide(L)
Molecule:VP2
Chain IDs:B
Chain Length:330
Number of Molecules:1
Biological Source:Echovirus E30
Polymer Type:polypeptide(L)
Molecule:VP3
Chain IDs:C
Chain Length:238
Number of Molecules:1
Biological Source:Echovirus E30
Polymer Type:polypeptide(L)
Molecule:Heavy chain
Chain IDs:D (auth: H)
Chain Length:216
Number of Molecules:1
Biological Source:Mus musculus
Polymer Type:polypeptide(L)
Molecule:Light chain
Chain IDs:E (auth: L)
Chain Length:213
Number of Molecules:1
Biological Source:Mus musculus
Ligand Molecules
Primary Citation
Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B.
Nat Commun 11 4419 4419 (2020)
PMID: 32887892 DOI: 10.1038/s41467-020-18250-w

Abstact

Echovirus 30 (E30), a serotype of Enterovirus B (EV-B), recently emerged as a major causative agent of aseptic meningitis worldwide. E30 is particularly devastating in the neonatal population and currently no vaccine or antiviral therapy is available. Here we characterize two highly potent E30-specific monoclonal antibodies, 6C5 and 4B10, which efficiently block binding of the virus to its attachment receptor CD55 and uncoating receptor FcRn. Combinations of 6C5 and 4B10 augment the sum of their individual anti-viral activities. High-resolution structures of E30-6C5-Fab and E30-4B10-Fab define the location and nature of epitopes targeted by the antibodies. 6C5 and 4B10 engage the capsid loci at the north rim of the canyon and in-canyon, respectively. Notably, these regions exhibit antigenic variability across EV-Bs, highlighting challenges in development of broad-spectrum antibodies. Our structures of these neutralizing antibodies of E30 are instructive for development of vaccines and therapeutics against EV-B infections.

Legend

Protein

Chemical

Disease

Primary Citation of related structures